Inclusion Criteria:  Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time. Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).  Exclusion Criteria:  - Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.